It was agreed by the Heads of Medicines Agencies (HMA) in 
Reykjavik on 28 February 2005 that by an agreed end-2009 deadline, the European 
regulatory agencies must have the infrastructure and processes in place to 
handle electronic-only eCTD submissions to successfully support the related 
decision-making processes for the authorisation of medicinal products within the 
European Union.
The IMB has fully adopted the European Guidance for eCTD 
(electronic Common Technical Document) and NeeS (Non-eCTD electronic 
submissions).   The transition to electronic submissions brings with it several 
advantages, not only the obvious reduction in printing, archiving and 
transportation costs, but also facilitates consistency in information viewed 
across agencies, the ability to manage the lifecycle of the product, and 
improved navigation and assessment of documentation.  
To find more information to use the below mentioned 
weblink
 
 
No comments:
Post a Comment